Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Emory University
Pfizer
St. Jude Children's Research Hospital
Pfizer
Seattle Children's Hospital
Nested Therapeutics, Inc
St. Jude Children's Research Hospital
Pfizer
Ikena Oncology
Mayo Clinic
Day One Biopharmaceuticals, Inc.
Emory University
Eli Lilly and Company
Thomas Jefferson University
Thomas Jefferson University
BerGenBio ASA
ABM Therapeutics Corporation
ABM Therapeutics Corporation
National Institutes of Health Clinical Center (CC)
University of Florida
National Cancer Institute (NCI)
Deciphera Pharmaceuticals, LLC
Sumitomo Pharma America, Inc.
Karyopharm Therapeutics Inc
Quadriga Biosciences, Inc.
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Case Comprehensive Cancer Center
Celgene
Tocagen Inc.
IGF Oncology, LLC
University of Illinois at Chicago
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Shenzhen Second People's Hospital
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Children's Oncology Group
Angiochem Inc
Children's Oncology Group
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University